New York State Common Retirement Fund Raises Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

New York State Common Retirement Fund grew its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 625.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 5,800 shares of the biotechnology company’s stock after acquiring an additional 5,000 shares during the period. New York State Common Retirement Fund’s holdings in Capricor Therapeutics were worth $80,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Point72 Asset Management L.P. bought a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $3,806,000. PFM Health Sciences LP purchased a new position in Capricor Therapeutics during the third quarter valued at $2,324,000. State Street Corp boosted its holdings in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after buying an additional 111,291 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at $938,000. Finally, JPMorgan Chase & Co. grew its position in shares of Capricor Therapeutics by 419.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock worth $855,000 after buying an additional 45,381 shares during the period. Institutional investors own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CAPR. HC Wainwright reissued a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Tuesday. Cantor Fitzgerald lifted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Down 7.7 %

Shares of CAPR opened at $12.65 on Thursday. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The company has a market capitalization of $575.20 million, a P/E ratio of -11.93 and a beta of 4.08. The firm has a 50 day moving average of $14.40 and a 200 day moving average of $13.93.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.